透過您的圖書館登入
IP:18.191.171.235
  • 期刊

九十九年疫苗與類毒素檢驗封緘案件及實施運送規範成效分析

Annual Surveillance of Batch Released Vaccines and Toxoids in Taiwan, 2010

摘要


本報告係本局99年度執行生物藥品中疫苗與類毒素檢驗封緘案件之統計分析,及自99年5月27日公布實施「疫苗檢驗封緘作業送驗檢體抽樣現場應注意事項」之成效討論,藉以瞭解國人99年度使用疫苗的整體品質概況,並確保各疫苗與類毒素品質是否能符合中華藥典及各原產國規範。99年度廠商申請疫苗與類毒素檢驗封緘產品共161批,經判讀溫度記錄器後,其中11批疫苗部份運送紙箱內溫度與「疫苗檢驗封緘作業送驗檢體抽樣現場應注意事項」所規範不符,所以僅接受運送溫度合格部分之檢驗封緘案。99年總計完成161批檢驗,放行12,751,951劑,其中國內生產為46批5,870,554劑,批次及劑量分別佔28.6及46.0%,而國外輸入115批6,881,397劑,批次及劑量分別佔71.4及54.0%。經逐批進行25項2,175次之檢驗與審查,結果均符合中華藥典或原廠之規定,並予以核發封緘證明書。已放行之161批產品中153批疫苗與類毒素,分別來自7家疫苗公司所持有之25張許可證,另外8批產品尚未領有許可證,係由衛生署疾病管制局向本局申請專案進口之特殊用途疫苗。此外,完成批次數及劑量數皆以國光生物科技股份有限公司為最多。依疫苗預防的病原種類統計,放行批次數前3名依序為流行性感冒疫苗、麻疹腮腺炎德國麻疹混合疫苗及日本腦炎疫苗,放行劑量數前3名則為流行性感冒疫苗、破傷風類毒素及五合一疫苗(吸著白喉破傷風非細胞型百日咳、不活化型小兒麻痺及b型流行性感冒嗜血桿菌混合疫苗)。此外,為確保疫苗於規範溫度下運送,於99年公告「疫苗檢驗封緘作業送驗檢體抽樣現場應注意事項」,多數輸入廠商已依規範使用電子式溫度記錄器,預計將於100年度全面性使用。另,4家廠商檢送運送溫度相關資料提出申請各品項疫苗之運送溫度容許範圍,計29項疫苗已核定。

關鍵字

疫苗 類毒素 檢驗封緘

並列摘要


Batch release for biological products is an important regulation for safety and quality and is carried in accordance with the Chinese pharmacopoeia in Taiwan. In this study, we summarized and analyzed the batch release of domestic and imported vaccine and toxoids. One hundred and sixty one batches (12,751,951 doses) belonging to 25 licenses and 7 vaccine companies were investigated in the batch release tests in 2010. Among them, proportions of domestic and imported products in batches and doses were 28.6% (46 batches) and 46.0% (5,870,554 doses), and 71.4% (115 batches) and 54.0% (6,881,397 doses), respectively. Totally, the performed examinations covered 25 items 2,175 tests. All test results were conformed to the regulations in Taiwan. In summary, order of the most release batches was influenza vaccines, measles/mumps/rubella vaccine and JE vaccine. Order of the most release doses was influenza vaccines, tetanus toxoids and DTP/polio/hib combination vaccine. These results could be provided for the further batch release regulations.

並列關鍵字

vaccine toxoid batch release

延伸閱讀